Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGM831 Monotherapy and Combination in Advanced Solid Tumors
NCT05215574Phase 1Active, not recruiting
- Sponsor
- NGM Biopharmaceuticals
- Start
- Mar 2022
- Primary completion
- Jul 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of NGM831 in pancreatic cancer (PC), breast cancer, gastric cancer (GC) and 13 more (3 arms), sponsored by NGM Biopharmaceuticals. Primary endpoints: Number of Patients with Dose-limiting Toxicities at 21 days and Incidence of Adverse Events at 24 months. Started Mar 2022; status: active, not recruiting.
02
Drugs
NGM831
03
Conditions
pancreatic cancer (PC)breast cancergastric cancer (GC)non-small cell lung cancer (NSCLC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05215574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05215574.